

29 January 2018

## ASX Announcement

### Pentrox approved in Austria

Medical Developments International Limited (ASX: MVP) is delighted to announce that Pentrox has been approved for sale in Austria.

The Austrian Medicines Agency issued the Marketing Authorisation on 19 January 2018.

MVP CEO, Mr. John Sharman said, "It is exciting to see a further Marketing Authorisation come through so quickly after the Icelandic and Danish approvals announced last week. We expect the remaining 19 countries will issue Marketing Authorisations' to approve the sale of Pentrox in their country over the coming months."

#### European approval progress

- Approved
- Approved (National Phase)
- Future Approvals





Enquiries:

David Williams  
Chairman  
Medical Developments International Ltd  
+61 (0) 414 383 593

John Sharman  
Chief Executive Officer  
Medical Developments International Ltd  
+61 (3) 9547 1888



### **About Pentrox**

Pentrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Pentrox has been used safely and effectively for more than 40 years in Australia with excess of 5.0 million units sold. There is growing interest in Pentrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

### **About Medical Developments International Ltd**

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Pentrox®, a fast acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

### **About the Mundipharma network**

The Mundipharma global network of privately-owned independent associated companies was founded in 1956 by doctors, and now operates in over 120 countries worldwide. We are focused on developing business partnerships to identify and accelerate meaningful technology across an increasingly diverse portfolio of therapy areas including respiratory, oncology, pain, and biosimilars. Consistent with our entrepreneurial heritage, we like to think we see what others don't by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. For more information please visit: [www.mundipharma.com](http://www.mundipharma.com).